Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Governance Documents Committees Year None202420232022 August 8, 2024 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments May 29, 2024 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day May 29, 2024 Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors May 9, 2024 Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments April 22, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares April 18, 2024 Biohaven Announces Pricing of $230 Million Public Offering of Common Shares April 17, 2024 Biohaven Announces Proposed Public Offering of Common Shares April 13, 2024 Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates February 29, 2024 Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments January 8, 2024 Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology Current page 1 Page 2 ► ► Displaying 1 - 10 of 11 BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Data Provided by Refinitiv. Minimum 15 minutes delayed.
Year None202420232022 August 8, 2024 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments May 29, 2024 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day May 29, 2024 Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors May 9, 2024 Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments April 22, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares April 18, 2024 Biohaven Announces Pricing of $230 Million Public Offering of Common Shares April 17, 2024 Biohaven Announces Proposed Public Offering of Common Shares April 13, 2024 Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates February 29, 2024 Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments January 8, 2024 Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology Current page 1 Page 2 ► ► Displaying 1 - 10 of 11
August 8, 2024 Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments
May 29, 2024 Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
May 29, 2024 Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
April 22, 2024 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
April 13, 2024 Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
February 29, 2024 Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
January 8, 2024 Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therapeutic Indications in Neuroscience, Immunology and Oncology
